# Pyxis Oncology (PYXS) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PYXS
## Company Profile
- Ticker: PYXS
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Oncology
## Stock Data
- Close: 3.13 USD
- Market cap: 108337874.22 USD
- Last updated: 2026-08-05
## Business Overview
### Tumor-Microenvironment ADC Company
Pyxis Oncology develops antibody-drug conjugates for difficult-to-treat cancers, with a strategy that targets structural components of the tumor microenvironment.
### MICVO
Micvotabart pelidotin, or MICVO, targets extradomain-B fibronectin, a non-cellular component enriched in tumor tissue. This approach is intended to deliver a cytotoxic payload across heterogeneous tumors without relying on uniform tumor-cell antigen expression.
### Head and Neck Cancer Focus
MICVO is being evaluated as monotherapy in previously treated recurrent or metastatic head and neck squamous cell carcinoma and with pembrolizumab in the first-line setting.
## Why The Stock Is Moving

As of Aug 5, 2026, PYXS closed down 0.95% at $3.13. No new same-company headline was identified in the current news window.

## Future Catalysts

- Updated Phase 1 MICVO monotherapy data in second-line or later head and neck cancer are expected around mid-2026.
- Updated Phase 1/2 data for MICVO plus pembrolizumab in first-line recurrent or metastatic head and neck cancer are expected in the second half of 2026.

## Recent News
- 2026-06-30 11:30 EST — [Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones](https://biopharmsignal.com/news/PYXS/pyxis-oncology-announces-up-to-114-million-private-placement-financing-to-advanc-a7414ffd) — Source: Pyxis Oncology
- 2026-05-14 11:00 EST — [Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones](https://biopharmsignal.com/news/PYXS/pyxis-oncology-reports-first-quarter-2026-financial-results-and-advances-micvo-t-3b0d67d9) — Source: Pyxis Oncology
- 2026-05-13 11:30 EST — [Pyxis Oncology to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-participate-in-upcoming-investor-conferences-c593dd86) — Source: Pyxis Oncology
- 2026-05-07 20:05 EST — [Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer](https://biopharmsignal.com/news/PYXS/pyxis-oncology-appoints-nelson-azoulay-as-chief-business-officer-ac9a049b) — Source: Pyxis Oncology
- 2026-04-17 20:05 EST — [Pyxis Oncology to Present New Preclinical Data Showing Synergistic Anti-Tumor Activity in a HNSCC model with maMICVO in Combination with Anti-PD-1 at AACR 2026](https://biopharmsignal.com/news/PYXS/pyxis-oncology-to-present-new-preclinical-data-showing-synergistic-anti-tumor-ac-5b636925) — Source: Pyxis Oncology